Condition
Acromegaly Due to Pituitary Adenoma
Total Trials
5
Recruiting
2
Active
2
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (2)
P 3 (1)
Trial Status
Recruiting2
Not Yet Recruiting1
Unknown1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07306325Not Yet RecruitingPrimary
Ultrasound in Predicting Difficult Intubation in Acromegaly Patients
NCT07179926RecruitingPrimary
Effects of Pasireotide Lar Therapy on Bone Metabolism
NCT06949891Not ApplicableRecruitingPrimary
KETOgenic Diet Therapy in Patients With ACROmegaly
NCT03807076Not ApplicableCompletedPrimary
Modulating the GIP System in Patients With Acromegaly Due to a Pituitary Tumor
NCT03439709Phase 3UnknownPrimary
Multicenter Evaluation of the Effect of Upfront Radiosurgery on Residual Growth Hormone-secreting Pituitary Adenoma
Showing all 5 trials